Advancing the Science

Mayo Clinic Medical Science Blog – an eclectic collection of research- and research education-related stories: feature stories, mini news bites, learning opportunities, profiles and more from Mayo Clinic.


Member has chosen to not make this information public.

Posts (175)

Tue, Jul 2 6:00am · Research News Roundup-June 2019

The Mayo Clinic Research News Roundup includes brief summaries and links to research news releases from the past month. It also connects readers to related resources. Read on for more information from Mayo Clinic Research.

Sometimes a physician thinks the outcome of a patient’s treatment is a great success. Sometimes that patient thinks it was a flop.

That disconnect may go unexpressed by patients or unrecognized by health care providers. Even if there is a “outcome satisfaction” survey, it may not collect the right information or the outcomes measured for patients and physicians may be different and thus not comparable.

Shawn O’Driscoll, M.D., a Mayo Clinic orthopedic surgeon, wanted to develop an assessment process that would be informative, reliable and flexible enough to use across medical specialties.

Read about his research in developing the Summary Outcome Determination Score.

Micronutrient deficiencies, including vitamins B12 and D, as well as folate, iron, zinc and copper, are common in adults at the time of diagnosis with celiac disease. These deficiencies should be addressed at that time, according to a study by Mayo Clinic researchers.

The retrospective study of 309 adults newly diagnosed with celiac disease at Mayo Clinic from 2000 to 2014 also found that low body weight and weight loss, which are commonly associated with celiac disease, were less common. Weight loss was seen in only 25.2% of patients, and the average body mass index was categorized as overweight. The study will appear in the July print issue of Mayo Clinic Proceedings.

Despite improvements in median and short-term survival rates for patients with glioblastoma, the most common brain tumor in adults, the percentage of patients achieving five-year survival remains low, according to new Mayo Clinic research.

A study published June 20 in Mayo Clinic Proceedings finds that little has changed in terms of five-year survival — only 5.5% of patients live for five years after diagnosis — and calls for more aggressive treatments to be considered for all glioblastoma patients.

A new study by Mayo Clinic researchers may have broad implications for treatment of patients with predominantly benign thyroid disease and newly treated hypothyroidism.

The study published in the Mayo Clinic Proceedings July print edition, looked at whether generic and brand-name levothyroxine therapy affected hospitalization for cardiovascular events for those patients who are more at risk of coronary heart disease and heart failure. Levothyroxine is the most prescribed medication in the U.S., with more than 23 million prescriptions written annually.

A Minnesota statewide bipartisan initiative is transforming health care from a focus on treating disease to one of tapping the body’s ability to heal itself. Regenerative Medicine Minnesota is a legislative initiative aimed at improving health by advancing regenerative medicine in research, technology, education and patient care across the state.

The 2019 annual meeting was held June 17, in Rochester, and co-chairs Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine and Jakub Tolar, M.D., Ph.D., dean of the Medical School and vice president for Clinical Affairs at the University of Minnesota, highlighted six “firsts” in advancing regenerative medicine toward patient care.

Read about them in the news release.

A generous $32 million gift from the New York-based Anna-Maria and Stephen Kellen Foundation will enable Mayo Clinic to expand its research mission with the construction of a four-story, 64,000-square-foot research building in Rochester, Minn.

“We cannot overstate our gratitude to the Anna-Maria and Stephen Kellen Foundation,” says Gianrico Farrugia, M.D., Mayo Clinic’s president and CEO. “Research is critical to infusing new knowledge into patient care. It paves the way to solve serious or complex medical challenges for our patients at Mayo as well as patients around the world. This remarkable gift will allow us to meet a critical need for research space on our Rochester campus.”

Discrimination and bias in health care were the subject of some of Mayo’s studies.

Mayo Clinic Cancer Center has long had a strong presence at the American Society of Clinical Oncology’s annual meeting – the largest gathering of its kind, and #ASCO19 was no exception. This linked blog post contains brief summaries of (and links to) the four Mayo news releases sent out from the 2019 ASCO Annual Meeting in Chicago.


Find out more:

Mon, Jul 1 6:00am · Community preparedness for future outbreaks: Lessons from whooping cough

the news has contained many stories of illness or death that could have been
prevented by vaccination. Although in 2019 the stories have mostly been about
measles, in 2016 it was pertussis, or whooping cough, as it was in 2012, and

The Centers for Disease Control estimates 24.1 million cases of whooping cough occur each year worldwide, resulting in 160,700 deaths. As with measles, the most effective way to prevent whooping cough is through vaccination.

Recently Young Juhn, M.D., a clinical informatistician, pediatrician and population health researcher at Mayo Clinic, led a study using spatio-temporal, or hot-spot, analysis to better understand the pertussis outbreaks. His team analyzed the onset and spread of pertussis during two time periods, in Olmsted County, Minnesota, using a microbiology database and the Rochester Epidemiology Project. This unique medical records linkage system and longtime regional research collaborative originated in Olmsted County, Minnesota, and now includes 27 counties across Minnesota and Wisconsin.

Young Juhn, M.D.

Dr. Juhn and his team found that during 2004-2005 and 2012, whooping cough was diagnosed in Olmsted County at rates 5-10 times higher than average, as well as significantly higher than across the rest of Minnesota. Only whooping cough cases with diagnosis as confirmed by laboratory testing conducted by Mayo Clinic Laboratories were included. No individuals were counted who did not have confirmed laboratory results.

found that adolescents (age 11-13) had the highest incidence rate during both
outbreaks. Furthermore, the researchers observed that early in both outbreaks,
a specific geographic area/neighborhood had the highest incidence levels.

locations have not been typically taken into account as a risk factor for
infectious diseases,” says Dr. Juhn. “However, our study results indicate
that we need to change that.”

Dr. Juhn
can’t say yet why that neighborhood was disproportionately affected, but he has
some theories he is pursuing with his research team.

next steps are to further characterize children living in this area compared to
other areas,” he says. “We want to examine school attendance, school
bus route, after school activities, and so forth.”

addition, Dr. Juhn and his fellow researchers see an opportunity to use the
rich data of electronic health records, including the resources of the Rochester
Epidemiology Project, to examine how well the pertussis vaccine helps provide
herd immunity, and also whether its protective effect lessens over time since

the team has several questions they still want to answer, Dr. Juhn says,
“Vaccination is still the best strategy to prevent whooping cough and
reduce its spread.”

Dr. Juhn
also encourages parents and teachers to encourage hand washing and other
precautions to prevent spread of infectious diseases. He also says that as
public health organizations become aware of whooping cough diagnoses,
coordination with the school district for early recognition and timely
isolation of cases could help prevent spread.

In their
continuing investigation around whooping cough, Dr. Juhn and his team are
planning to test and implement an innovative approach at a population level
called precision population medicine.

He says
that the geographic hotspots identified now and in the future could help them
to identify “first, which children and adolescents reside in such
geographic areas; second, which are susceptible to whooping cough due to not
up-to-date vaccinations; and finally, which schools they attend.”

“We need to educate parents and teachers about whooping cough and other common infectious diseases – both about symptoms and prevention,” Dr. Juhn says. “In Olmsted and Dodge counties in particular, we have partnerships with the schools and public health department already, through which we may be able to offer this and other vaccinations at school settings such as the School Flu Vaccine Program, making it easier and more timely for parents to protect their children.”

Dr. Juhn
reiterates that public health issues such as this are best addressed through
interagency coordination – wherever the outbreak may occur. He believes that understanding
historical trends in the spread of disease is “an important aspect of
improving a community’s preparedness for future outbreaks of emerging and
re-remerging infectious diseases.”

also could provide an opportunity to assess and address unmet health needs of
geographically under-served populations leading to health disparities,” he

addition to Dr. Juhn, the research team included:

  • Chung-Il Wi, M.D., and Euijung Ryu, Ph.D., of Mayo Clinic
  • Philip Wheeler, research consultant, former director of Olmsted and Rochester Planning Department
  • Harsheen Kaur, M.D., University of New Mexico
  • Dohyeong Kim, Ph.D., University of Texas


About the Rochester Epidemiology Project

The Rochester Epidemiology Project (REP) is a collaboration
of clinics, hospitals, and other medical facilities in Minnesota and Wisconsin
and involves community members who have agreed to share their medical records
for research. Using medical record information, medical scientists can discover
what causes the diseases, how patients respond to medical and surgical
therapies, and what will happen to patients in the future. Research studies
conducted in the local community may improve the health of people both locally
and globally.

The REP receives administrative support from the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Improving public health is in alignment with the center’s overall goal to transform the experience of health and health care.

Wed, Jun 19 6:00am · App may make diabetes self-management and personalized health care decisions easier

young woman on city street looking at her phone

Bithika Thompson, M.D., an endocrinologist at Mayo Clinic in Phoenix, and M. Adela Grando, PhD., a biomedical informaticist at Arizona State University, recently teamed up on a health care research project that could transform the way individuals manage their diabetes.

1 diabetes is a chronic disease that affects more than 1.2 million people in
the U.S. There is no cure for Type 1 diabetes. Patients must consistently
engage with ongoing self-management behaviors to manage the disease effectively
and prevent the numerous complications that can result from poorly controlled diabetes.
These self-management behaviors include frequent monitoring of blood glucose
levels, adherence to diet, and administration of insulin based on blood sugar
levels and carbohydrates consumed.

screen shot of app

the complexity of managing these behaviors in daily life makes diabetes
management difficult. When the researchers started the project, they wanted to
better understand patient behaviors with respect to diabetes self-management.
Armed with that knowledge, they and their team hoped to develop custom
interventions that would help each person better control their blood glucose
levels, thereby lessening the likelihood of diabetes-related adverse health

Specifically, they developed and tested a new way to design individualized data-driven educational interventions to improve Type 1 diabetes adherence. To do this, the researchers collected:

  • Real-time self-reported data collected daily by a smartphone app
    they had previously developed,
  • Objective data collected daily from the patients’ insulin pump
    and continuous glucose monitoring systems, and
  • Patient disease and device comprehension and self-management routines,
    as captured through surveys and interviews.

The app tracks
real-time information such as exercise plans, food and beverage intake, and
diabetes compensation techniques (eating a snack prior to exercise to prevent a
low blood sugar).

Additional computer
algorithms were developed to automatically collect and analyze all the
information brought in, and provide actionable information for clinicians.

have unique self-care preferences and behaviors that should be taken into
consideration by clinicians,” says Dr. Thompson, “particularly as
patients are more likely to achieve adherence when incorporating lifestyle and
self-management preferences.”

on what the team found out about patient behavior, they were able to help
develop more specific educational materials for patients. They also developed
talking points for clinicians to lead discussions on the patients’ individual
self-management behaviors that could lead to positive or negative health

hope that targeted patient education, and facilitating individualized
conversations, will lead to better health outcomes,” she says.

This research was funded by Arizona State University and the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.


Mon, Jun 17 6:00am · Finding what works best to stop osteoporosis in its tracks

two older women walking outdoors

According to the International Osteoporosis Foundation, more than 200 million people worldwide suffer from osteoporosis, or insufficient regeneration of bone tissue and fragile bones. At least 40% of postmenopausal women and 15-30% of older men will sustain one or more fractures due to fragility. Osteopenia, a lesser form of bone loss, affects many millions as well, and may progress to a full osteoporosis diagnosis.

Because of the widespread nature of these disorders, and the
associated risk of fractures and related health issues, many treatments have
been developed. There are numerous medications and hormone treatments used to slow
or prevent bone loss, each with different indications and side effect profiles.
The variety of treatments and volume of related information can be difficult
for physicians to sort through to find the appropriate therapy for their

effectiveness research

Illustration of a portion of spine, with a close-up section of normal bone and osteoporotic bone.

“There are too many drugs that are used for osteoporosis,” says M. Hassan Murad, M.D., an internal medicine doctor and a clinical epidemiologist in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. “We wanted to compare them so that patients and physicians can make informed decisions.”

In order to determine which treatments work best, medical
researchers conduct comparative effectiveness research, in which they collect
and analyze the results of many clinical trials testing treatments for a
particular disease or condition. This can be done using a complex statistical
technique called network meta-analysis. The researchers then figure out which
interventions consistently rise to the top as being most effective.

Dr. Murad, who also leads Mayo Clinic’s Evidence-Based Practice Center, accepted the challenge of the Endocrine Society to provide the evidence to support the society’s guidelines for the treatment of postmenopausal women with osteoporosis.

practice recommendations

His multidisciplinary team reviewed and analyzed the results from 107 randomized clinical trials that enrolled postmenopausal women with primary osteoporosis or osteopenia and evaluated different treatments to prevent hip, vertebral (back/spine) or other fractures. These studies, conducted around the world, tested one or more of the following interventions: various bisphosphonates, teriparatide, selective estrogen receptor modulators, denosumab, abaloparatide, romosozumab, estrogen with or without progesterone, calcitonin, lasofoxifene, strontium ranelate, tibolone, PTH 1-84, calcium, or vitamin D.

They found that some treatments did indeed rise to the top
as most effective for halting the progression of osteoporosis and resulting
bone fragility.

“The most effective treatments to prevent fractures
were bisphosphonates and some newer medications: romosozumab, denosumab and
teriparatide,” says Dr. Murad.

It is possible that these findings could be practice
changing, he says. “When physicians prescribe these medications to women
with osteoporosis, they can use the results of this study to guide their

The research identified several effective treatments, so Dr.
Murad says, “Patients should ask about side effects and costs, as well as
ease of administration – some of these drugs are injectable and some are orals.”


The Mayo Clinic Evidence-Based Practice Center is so designated by the Agency for Healthcare Research and Quality. Recently it also became designated as a Cochrane affiliate within the Cochrane US Network. The evidence-based practice research program seeks to improve the quality, effectiveness and appropriateness of health care by synthesizing research evidence and facilitating the translation findings into clinical practice.

Related resources:

Wed, Jun 5 6:00am · Mayo Clinic at ASCO 2019

Every year the American Society of Clinical Oncology (ASCO) hosts a gathering of cancer researchers and clinicians from around the world to teach and learn from each other, sharing their research and innovations in patient care.

ASCO’s mission is “conquering cancer through research education, and promotion of the highest quality patient care” – a theme that Mayo Clinic Cancer Center is in full agreement with.

Mayo Clinic has long had a strong presence at #ASCO19 – the largest gathering of its kind, and 2019 was no exception. Below are brief summaries (and links to) of Mayo news releases sent out from the 2019 ASCO Annual Meeting in Chicago.

Two studies that explore types of discrimination and gender bias in health care organizations were presented by Mayo Clinic researchers.

Katharine Price, M.D., a medical oncologist, and Rahma Warsame, M.D., a hematologist, presented an abstract that reviews discrimination and inclusion among hematology and oncology trainees. Their study involved anonymous telephone interviews with 17 hematology and oncology fellows regarding discrimination, harassment and inclusion. According to the study, discrimination toward fellows was common, and it was more common from patients than staff.

The second study, led by Narjust Duma, M.D., chief hematology-oncology fellow at the Rochester, Minnesota, campus of Mayo Clinic, zeros in on speaker introductions and how professional titles have been used at past American Society of Clinical Oncology annual meetings.

“Gender bias can be reinforced through the use of gender-subordinating language and differences in forms of address,” Dr. Duma says.

“Our results suggest that unconscious bias may be present and be a driver of gender disparities in medicine.”

Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventive medicine.

A new study by Mayo Clinic and collaborators at the University of Manitoba and CancerCare Manitoba suggests that when women at high risk are presented with personalized genetic information, they’re more likely to take preventative medications to reduce their chance of developing breast cancer. The research involved a new blood test developed by Mayo Clinic to identify women at higher genetic risk for developing breast cancer.

The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers. The study was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.

The findings are in line with a smaller trial in 2013 by researchers in Spain. “In conjunction with the Spanish data, this trial may support a change in clinical practice,” the study says.

“At present, the standard of care for smoldering multiple myeloma is observation without therapy,” says S. Vincent Rajkumar, M.D., a Mayo Clinic hematologist and senior author of the trial. “We found that treatment of smoldering myeloma delays progression to symptomatic myeloma and can prevent damage to organs that occurs in multiple myeloma.”

New studies on early detection of colorectal cancer and the quality-of-life impact of cell therapy were among several Mayo Clinic presentations at the American Society of Clinical Oncology annual meeting in Chicago.

Hao Xie, M.D., Ph.D., a Mayo Clinic hematology-oncology fellow, presented an abstract, “Methylated DNA Markers in Primary and Metastatic Colorectal Cancers,” that indicates the DNA markers are broadly informative for early detection of cancer.

Also mentioned in this news release was a presentation by Surbhi Sidana, M.B.B.S., an advanced hematology fellow at Mayo Clinic.

Her study, “Quality of Life in Patients Undergoing CAR-T Therapy Versus Stem Cell Transplant,” suggests patients receiving chimeric antigen receptor therapy (CAR-T cell therapy) do not experience a more significant decline in quality of life, compared with patients undergoing a bone marrow stem cell transplant using their own or donor stem cells.

These news releases cover only a tiny portion of the cancer research shared at #ASCO19. You can visit the conference website to find the full listing of Mayo Clinic research highlighted at #ASCO19.


Related resources:

Tue, Jun 4 6:00am · Research News Roundup-May 2019

three male researchers in suits in lab, Dr. Gores on right

The Mayo Clinic Research News Roundup includes brief summaries and links to research- and research education-related news releases from the past month. It also connects readers to additional resources of relevance. Read on for more information from Mayo Clinic Research.

Mayo Clinic researchers are among international experts who presented findings at Digestive Disease Week 2019, the world’s largest gathering of physicians, researchers and industry leaders in gastroenterology and related fields.

Digestive Disease Week 2019, May 18–21, 2019, featured 5,400 lectures, poster presentations and oral abstract presentations. Read the news release for more information on some of the Mayo Clinic research that was presented.

Surgical patients receiving the opioid tramadol have a somewhat higher risk of prolonged use than those receiving other common opioids, new Mayo Clinic research finds. However, the Drug Enforcement Administration (DEA) classifies tramadol as a Schedule IV controlled substance, meaning it’s considered to have a lower risk of addiction and abuse than Schedule II opioids, such as oxycodone and hydrocodone. The study was published May 14 in The BMJ.

“This data will force us to reevaluate our postsurgical prescribing guidelines,” says lead author Cornelius Thiels, D.O., a general surgery resident in Mayo Clinic School of Graduate Medical Education. “And while tramadol may still be an acceptable option for some patients, our data suggests we should be as cautious with tramadol as we are with other short-acting opioids.”

The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder. This rare but severe autoimmune inflammatory disorder can cause blindness, paralysis and death.

Mayo Clinic researchers and international collaborators report their findings in a randomized, double blind, placebo-controlled study published in the New England Journal of Medicine. Their work also was presented in the Emerging Science Platform session, part of the American Academy of Neurology’s 71st Annual Meeting in Philadelphia May 410.

A less-invasive mastectomy that leaves the surface of the breast intact has become a safe option for more patients, including those whose breast cancer has spread to nearby lymph nodes or who have risk factors for surgical complications, a Mayo Clinic study shows. In the procedure, known as a nipple-sparing mastectomy, surgeons remove breast tissue, leaving the skin, nipple and areola, and immediately rebuild the breasts. The findings were presented at the American Society of Breast Surgeons annual meeting. 

Researchers evaluated nipple-sparing mastectomy outcomes in 769 women who had the procedure between 2009 to 2017. In all, the surgery was performed on 1,301 breasts during the study period.

Patients diagnosed with rheumatoid arthritis often are affected by functional disability a year or two before the disease is diagnosed, according to new Mayo Clinic research.

The results of the study, published in the June print edition of Mayo Clinic Proceedings, suggest that daily activities such as eating, dressing and walking are affected early in the course of the disease, and that most rheumatoid arthritis patients are affected by functional disability issues.

Several news releases were sent out between Friday, May 31, and Monday, June 3, from the American Society of Clinical Oncology annual meeting in Chicago. You can read about these findings in cancer research in the Advancing the Science post Wednesday, June 5. You can also visit the Mayo Clinic News Network for these and other news releases and stories from Mayo Clinic.


SAVOR, SUBSCRIBE, SHARE:  Advancing the Science

  • If you enjoyed this article, you might want to subscribe for regular updates.
  • If you want to share this story with friends, social media links are at the top of the article.
  • And if you want to see other recent stories on the blog, the index page is a great place to start.

Fri, May 31 6:00am · Mayo Clinic practice transforming research at AcademyHealth's #ARM19

AcademyHealth’s Annual
Research Meeting
, June 2-4, 2019, in Washington, D.C., showcases “Today’s
research driving tomorrow’s outcomes.” It is an ideal venue to share
research findings from across the continuum of health care delivery.

The Mayo Clinic Robert
D. and Patricia E. Kern Center for the Science of Health Care Delivery

drives practice transformation at Mayo Clinic. Multidisciplinary teams are taking
control of the massive amounts of data that exist in health care today – from individual
health records, to research findings from around the world – to build a better
future for health care.

At #ARM19, Mayo Clinic
is on site in Booth #105/107, with many opportunities to meet health care
delivery researchers, learn about career options, and find out more about the
research. If you’ll be at #ARM19, stop by.

Here are all the other places you can hear from Mayo experts during #ARM19 (all rooms are in the Walter E. Washington Convention Center, except as noted):

Sunday, June 2

  • 8:45 – 10:15 a.m., Room 146 A

Special Session: Innovation
Opportunities for Risk Adjustment Under Value Based Payment

Session Chair Nilay Shah Ph.D., and Sarah Meier, Ph.D., Mayo Clinic; also Adele Shartzer, Ph.D., The Urban Institute; and Nathan Donnelly, New York eHealth Collaborative

  • 12:15 – 1:45 p.m., Exhibit Hall E

Poster A-227: Xiaoxi Yao, Ph.D.
Large Observational Data to Facilitate Personalized Shared Decision Making for a Recently Approved Cardiac Device

Poster A-331: Ramona DeJesus, M.D.
Experience and Expectations of Patients on Weight Loss: The Learning Health System Network

Poster A-357: Karen Schaepe, Ph.D.
Management of Uncertainty in Neonatal Periviability Counseling Sessions

Poster A-361: Kelly Viola
Understanding Patient Preferences in Developing Video Visit Environments

Poster A-448: Jonathan Inselman
Trends in Asthma Biologic Use in a Commercially Insured and Medicare Advantage U.S. Population

Mayo Clinic Presenter: Xiaoxi Yao, Ph.D.
Pairing Observational and Clinical Trial Data to Assess Cardiovascular Risk Reduction with Catheter Ablation for Atrial Fibrillation

  • 4 – 5:30 p.m., Room 147 B, Call for Abstracts Session: Organizational Innovations in Primary Care to Promote Patient and Provider Wellbeing

Mayo Clinic Presenter: Michelle Lampman, Ph.D.
Transforming Primary Care Practice with the Mayo Model of Community Care – A Qualitative Case Study of Implementation

  • 4 – 5:30 p.m., Room 144 A/B/C

Methods Session: HSR
Comes to Care: Innovations in Shared Decision Making and Patient-centered Care

Session Chair Victor Montori, M.D., and Ian Hargraves, Ph.D., Mayo Clinic; also Ming Tai-Seale, Ph.D., University of California – San Diego; Elissa Ozanne, Ph.D., University of Utah School of Medicine; and Megan Branda, University of Colorado – Denver Anschutz Medical Campus.

June 3

  • 8 – 9:15 a.m., Exhibit Hall E

Poster B-234
Shealeigh Funni
Pediatric Opioid Use in the Emergency Department: An 11 Year National Trend Study

Poster B-403
Rozalina McCoy, M.D.
Which Readmissions May be Preventable? Lessons Learned from a Post-Hospitalization Care

  • 11:30 a.m. – 1 p.m., Room 144 A/B/C

Methods Session: Practicing Natural Language Processing: Dos and Don’ts

Session Chair Alexander Turchin, M.D., Brigham and Women’s Hospital; with Hongfang Liu, Ph.D., Mayo Clinic; Stephane Meystre, M.D., Ph.D., Medical University of South Carolina; and Olga Patterson, Ph.D., University of Utah and VA Salt Lake City Health Care System.

  • 11:30 a.m. – 1 p.m., Room 152 A, Call for Abstracts Session: Trends and Challenges in Addressing Critical Issues for the Frontline Low Wage Workforce

Mayo Clinic Presenter: Jason Egginton
Reconsidering Burnout in Allied Health Staff: Assessing Work Unit Well-Being and Joy

  • 1:15 – 2:45 p.m., Exhibit Hall E

Poster C-196
Shaheen Kurani
Place, Poverty, and Prevention: A Mixed Methods Study

Poster C-199
Riccardo Lemini, M.D.
Healthcare Disparities in Elective Surgery for Diverticulitis: Identifying the GAP in Care

Poster C-222
Jennifer Ridgeway, Ph.D.
Collecting and Analyzing Data in Complex Community-Practice Environment: Protocol and Lessons Learned from a Study on Cancer Screening Uptake Among Patients with Limited English Proficiency

Poster C-302
Lisa Nordan
Risk Assessment and Referral Tool to Identify Patients at Risk for Pancreatic Cancer

Poster C-306
Jennifer Ridgeway, Ph.D.
Tracing the Potential of Networks to Connect Providers and Improve Community Cancer Care: A Case Study of an Integrated Health Systems

Poster C-368
Molly Jeffery, Ph.D.
Prolonged Opioid Use Among Patients Receiving Tramadol for Acute Pain

Poster C-387
Lisa Nordan
How a Risk-Stratified Precision-Medicine Model for Stroke Patients Improved Outcomes and Reduced Costs

Poster C-425
Ye (Julia) Zhu, M.D., Ph.D.
Systematic Review of the Evidence on the Cost-Effectiveness of Pharmacogenomics-Guide Treatment for Cardiovascular Diseases

Poster C-472
Riccardo Lemini, M.D.
Stage II-III Colon Cancer: A Comparison of Survival Calculators

Poster C-545
Michelle Lampman, Ph.D.
A Composite Measure of Primary Care Performance within a Large Integrated Health System

  • 3 – 4:30 p.m., Room 146 C, Call
    for Abstracts Session
    Improving the Value of Health Care: Careful Examination of Low-value
    Services and Their Impact on Healthcare Costs, Utilization, and Outcomes

Session Chair: Rozalina McCoy, M.D., Mayo Clinic

  • 5 – 6:30 p.m., Marriott Marquis – Independence F/G/H, Podium Presentation:
    • Part 1: Case Studies: Application of AI to Improve Care
    • Part 2: AI, Friend or Foe: Insights from Clinicians, Researchers, Funders and Payors

Session co-Chair Rozalina McCoy, M.D., Che Ngufor, Ph.D., Molly Jeffrey, Ph.D., and Suraj Kapa, M.D., Mayo Clinic; with Session co-Chair Angela Thomas, Dr.Ph., and Raj Ratwani, Ph.D., MedStar Health Research Institute; Kerrie Holley, J.D., Optum; and Chris Dymek, Ed.D., Agency for Healthcare Research and Quality.

Mayo Clinic researchers also were co-authors on several projects presented by other researchers at the AcademyHealth 2019 Annual Research Meeting:


Tue, May 28 6:00am · Telerehabilitation improves quality of life for patients with late-stage cancers, reduces costs

A new study suggests that remotely delivering rehabilitation
services to patients with late-stage cancer improves their physical function,
pain and quality of life while allowing them to spend less time in hospitals
and nursing homes.

The results of a randomized clinical trial with 516 participants, led by Andrea Cheville, M.D., a Mayo Clinic physical medicine and rehabilitation physician are reported in a recent Mayo Clinic news release. Dr. Cheville also is the medical director of the Care Experience Program within the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.

Study findings are published in JAMA Oncology. They were of such import for practice
transformation, notes Dr. Cheville, that the journal also published what turned
out as a complimentary invited
, “Collaborative Telerehabilitation – A Smart Move for
Patients With Advanced Cancer.”

Andrea Cheville, M.D.

Dr. Cheville says this trial, supported by the center’s
study design, data collection and research coordination experts, is an example
of an innovative care option that meets patients where they are.

“Research drives everything we do for patients, and in
this case, our evidence shows that we have a new way to improve the health care
experience for our patients,” she says. “And telerehabilitation
appears to lead to lower health care costs too, reducing hospital and nursing
home stays as well as in-person care visits.”

Dr. Cheville’s multi-institutional team was the first ever
to study the use of telecare among complex and vulnerable patients with late stage
cancers. “The model that we used is novel and scalable,” she says,
“and aligns with Mayo’s vision of increasing remote care delivery.” 

The Mayo Clinic Kern Center for the Science of Health Care Delivery brings together unique capabilities, combining design methods, knowledge management, big data analysis, health care engineering principles and advanced simulations, to solve challenges for patients, providers and the health care system at large. The center’s goal is to translate discoveries into evidence-based, actionable treatments, processes and procedures.

Telerehabilitation research is one of the many ways Mayo Clinic extends knowledge and care to more people through innovative telemedicine platforms that improve access and outcomes for patients, and collaboration with other providers and researchers.


Related Resources:

Contact Us · Privacy Policy